Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units

Patricia J Baudry; Kim Nichol; Melanie DeCorby; Laura Mataseje; Michael R Mulvey; Daryl J Hoban; George G Zhanel

doi:10.1128/AAC.01176-07

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units

Antimicrob Agents Chemother. 2008 May;52(5):1846-9. doi: 10.1128/AAC.01176-07. Epub 2008 Feb 25.

Authors

Patricia J Baudry¹, Kim Nichol, Melanie DeCorby, Laura Mataseje, Michael R Mulvey, Daryl J Hoban, George G Zhanel

Affiliation

¹ Department of Medical Microbiology, Faculty of Medicine, University of Manitoba, Winnipeg, R3A 1R9, Manitoba, Canada. [email protected]

Abstract

Resistance profiles were compared among 18 extended-spectrum-beta-lactamase-producing (ESBL) and 27 acquired AmpC beta-lactamase-producing Escherichia coli isolates collected from Canadian intensive care units from 2005 to 2006. ESBL-producing E. coli isolates were more likely to be gentamicin resistant (P < 0.03), fluoroquinolone resistant (P < 0.0001), and multidrug resistant (P < 0.0001) than AmpC-producing E. coli isolates.

Publication types

Comparative Study
Research Support, Non-U.S. Gov't

MeSH terms

Bacterial Proteins / metabolism*
Canada
Drug Resistance, Multiple, Bacterial
Escherichia coli / drug effects*
Escherichia coli / enzymology*
Escherichia coli / isolation & purification
Escherichia coli Infections / microbiology
Fluoroquinolones / pharmacology
Gentamicins / pharmacology
Humans
Intensive Care Units*
Microbial Sensitivity Tests
beta-Lactamases / metabolism*

Substances

Bacterial Proteins
Fluoroquinolones
Gentamicins
AmpC beta-lactamases
beta-Lactamases